25
Views
3
CrossRef citations to date
0
Altmetric
Drug Evaluation

Pharmacoeconomic aspects of memantine (Ebixa®) in the treatment of Alzheimer’s disease

Pages 675-680 | Published online: 09 Jan 2014
 

Abstract

Severe dementia is a devastating condition causing great impairment in cognition and functional capacity. The costs associated with severe dementia are very high and the disease can have a major impact on the next of kin. Thus, any treatment that can influence the course of severe dementia would be of great value. Memantine (1amino3,5dimethyladamantane hydrochloride, CAS 4100521, Ebixa®) is a noncompetitive N-methyl-D-aspartate antagonist. It has been suggested that by inhibiting excessive stimulation of NMDA receptors, memantine may have the potential to provide both symptomatic improvement and neuroprotective effects in Alzheimer’s disease. In clinical trials on patients with moderate-to-severe Alzheimer’s disease, memantine has shown significant effects on clinical global impression of change, behavior and activities in daily life. In this survey, pharmacoeconomic results of memantine treatment from a prospective randomized 6-month US clinical trial are reviewed. Caregiver time was significantly lower in the memantine group and the resulting costs were also lower in the memantine group as compared with placebo. Combined with efficacy results, this may indicate cost-effectiveness. However, such a conclusion should be judged with some care since the long-term effects on resource utilization, costs and survival are not known.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.